Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:43:e2021103.
doi: 10.4178/epih.e2021103. Epub 2021 Dec 17.

Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study in Korea using extended landmark time analysis

Affiliations

Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study in Korea using extended landmark time analysis

Hwa Jeong Seo et al. Epidemiol Health. 2021.

Abstract

Objectives: This study investigated the effectiveness of early medication treatment and metformin use for cancer prevention in type 2 diabetes patients.

Methods: Population-based cohort data were used from the Korean National Health Insurance Service-National Sample Cohort database (KNHIS-NSC) for 2002-2013. Patient-specific medication prescription status was defined by the landmark time (LMT; a fixed time after cohort entry), considering both pre- and post-LMT prescriptions to control methodological biases in observational research. The LMT was set to 2 years. Logistic regression analysis with multivariable adjustment was conducted to analyze cancer incidence by patient-specific medication prescription status.

Results: Only 33.4% of the subjects were prescribed medication early (before the LMT) with compliance. Cancer incidence in individuals with early prescription and compliance was 25% lower (odds ratio [OR], 0.75; 95% confidence interval [CI], 0.67 to 0.84) than in those without. As early-prescribed medications, metformin monotherapy and metformin combination therapy were associated with 34% (OR, 0.66; 95% CI, 0.51 to 0.83) and 25% (OR, 0.75; 95% CI, 0.64 to 0.88) lower cancer risk than non-use, respectively. Patients who were prescribed late (post-LMT) but did not comply with the prescription had a 24% (OR, 1.24; 95% CI, 0.97 to 1.58) higher cancer incidence than non-users. Among patients who started monotherapy early without changes throughout the entire follow-up period, those who started on metformin had a 37% (OR, 0.63; 95% CI, 0.41 to 0.99) lower risk of cancer than non-metformin users.

Conclusions: Doctors must prescribe antidiabetic medication early, and patient compliance is required, regardless of the prescription time, to prevent cancer. Metformin monotherapy or combination therapy is recommended as an early prescription.

Keywords: Anticancer agents; Drug prescription; Medication compliance; Metformin; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare for this study.

Figures

Figure 1
Figure 1
Flowchart of the sampling procedure.
Figure 2
Figure 2
Medication prescription status; (A) early prescription with compliance, (B) early prescription with poor compliance, (C) late prescription with compliance, (D) late prescription with poor compliance, and (E) no prescription ever. TPD, total prescription days; LMT, landmark time.

Similar articles

Cited by

References

    1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. - PubMed
    1. Kim Y, Nho SJ, Woo G, Kim H, Park S, Kim Y, et al. Trends in the prevalence and management of major metabolic risk factors for chronic disease over 20 years: findings from the 1998–2018 Korea National Health and Nutrition Examination Survey. Epidemiol Health. 2021;43:e2021028. - PMC - PubMed
    1. Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res. 2019;11:3295–3313. - PMC - PubMed
    1. Kim HJ, Jee SH. Insulin resistance and cancer. Korean J Epidemiol. 2005;27:38–50. (Korean).
    1. Kim SK, Jang JY, Kim DL, Rhyu YA, Lee SE, Ko SH, et al. Site-specific cancer risk in patients with type 2 diabetes: a nationwide population-based cohort study in Korea. Korean J Intern Med. 2020;35:641–651. - PMC - PubMed

MeSH terms